BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 2000;32:228-232. [PMID: 10915728 DOI: 10.1053/jhep.2000.9409] [Cited by in Crossref: 253] [Cited by in F6Publishing: 239] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Gao X, Zhan M, Wang L, Ding Y, Niu J. Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC. J Hepatocell Carcinoma 2020;7:347-60. [PMID: 33299823 DOI: 10.2147/JHC.S279657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 Mori Y, Tamai H, Shingaki N, Moribata K, Shiraki T, Deguchi H, Ueda K, Enomoto S, Magari H, Inoue I. Diffuse intrahepatic recurrence after percutaneous radiofrequency ablation for solitary and small hepatocellular carcinoma. Hepatol Int. 2009;3:509-515. [PMID: 19669252 DOI: 10.1007/s12072-009-9131-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
3 Tanaka S, Shinkawa H, Tamori A, Takemura S, Takahashi S, Amano R, Kimura K, Ohira G, Kawada N, Kubo S. Surgical outcomes for hepatocellular carcinoma detected after hepatitis C virus eradiation by direct-acting antivirals. J Surg Oncol 2020;122:1543-52. [PMID: 32856301 DOI: 10.1002/jso.26184] [Reference Citation Analysis]
4 Kubo S, Takemura S, Sakata C, Urata Y, Uenishi T. Adjuvant therapy after curative resection for hepatocellular carcinoma associated with hepatitis virus. Liver Cancer. 2013;2:40-46. [PMID: 24159595 DOI: 10.1159/000346214] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
5 Borden EC, Jacobs B, Hollovary E, Rybicki L, Elson P, Olencki T, Triozzi P. Gene regulatory and clinical effects of interferon β in patients with metastatic melanoma: a phase II trial. J Interferon Cytokine Res 2011;31:433-40. [PMID: 21235385 DOI: 10.1089/jir.2010.0054] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
6 Kubo S, Takemura S, Uenishi T, Yamamoto T, Ohba K, Ogawa M, Hai S, Ichikawa T, Kodai S, Shinkawa H, Tanaka H. Second hepatic resection for recurrent hepatocellular carcinoma in patients with chronic hepatitis C. World J Surg 2008;32:632-8. [PMID: 18210185 DOI: 10.1007/s00268-007-9365-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
7 Sasaki A, Iwashita Y, Shibata K, Matsumoto T, Ohta M, Kitano S. Improved long-term survival after liver resection for hepatocellular carcinoma in the modern era: retrospective study from HCV-endemic areas. World J Surg. 2006;30:1567-1578. [PMID: 16855807 DOI: 10.1007/s00268-005-0249-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
8 Alric L, Duffaut M, Selves J, Sandre K, Mularczyck M, Izopet J, Desmorat H, Bureau C, Chaouche N, Dalbergue B, Vinel JP. Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial. J Hepatol 2001;35:272-8. [PMID: 11580151 DOI: 10.1016/s0168-8278(01)00110-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
9 Sakaguchi Y, Kudo M, Fukunaga T, Minami Y, Chung H, Kawasaki T. Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology. 2005;48:64-70. [PMID: 15785092 DOI: 10.1159/000082097] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 2.4] [Reference Citation Analysis]
10 Aguayo A, Patt YZ. Liver cancer. Clin Liver Dis. 2001;5:479-507. [PMID: 11385973 DOI: 10.1016/s1089-3261(05)70175-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
11 Ishii H, Yamamoto J, Ikari T. Adjuvant treatments for resectable hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2008;15:459-462. [PMID: 18836796 DOI: 10.1007/s00534-008-1359-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
12 Spangenberg HC, Thimme R, Blum HE. Advances in prevention and diagnosis of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2008;2:425-33. [PMID: 19072390 DOI: 10.1586/17474124.2.3.425] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
13 Craxì A, Cammà C. Does chemotherapy prevent HCV-related hepatocellular carcinoma? Cons. Dig Liver Dis. 2010;42 Suppl 3:S287-S292. [PMID: 20547316 DOI: 10.1016/s1590-8658(10)60518-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Matar P, Alaniz L, Rozados V, Aquino JB, Malvicini M, Atorrasagasti C, Gidekel M, Silva M, Scharovsky OG, Mazzolini G. Immunotherapy for liver tumors: present status and future prospects. J Biomed Sci. 2009;16:30. [PMID: 19272130 DOI: 10.1186/1423-0127-16-30] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
15 Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, Yamazaki M, Yamao J, Mitoro A, Sawai M, Yoshida M, Fujimoto M, Tsujimoto T, Kawaratani H, Uemura M, Fukui H. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. Journal of Hepatology 2009;51:315-21. [DOI: 10.1016/j.jhep.2009.04.011] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
16 Jeong SC, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol 2007;13:5343-50. [PMID: 17879404 DOI: 10.3748/wjg.v13.i40.5343] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
17 Mathurin P, Raynard B, Dharancy S, Kirzin S, Fallik D, Pruvot F, Roumilhac D, Canva V, Paris J, Chaput J, Naveau S. Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma: META-ANALYSIS: ADJUVANT THERAPY AFTER CURATIVE LIVER RESECTION FOR HCC. Alimentary Pharmacology & Therapeutics 2003;17:1247-61. [DOI: 10.1046/j.1365-2036.2003.01580.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 4.2] [Reference Citation Analysis]
18 Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg. 2002;89:418-422. [PMID: 11952580 DOI: 10.1046/j.0007-1323.2001.02054.x] [Cited by in Crossref: 118] [Cited by in F6Publishing: 112] [Article Influence: 6.2] [Reference Citation Analysis]
19 Riaz IB, Riaz H, Riaz T, Rahman S, Amir M, Badshah MB, Kazi AN. Role of vitamin K2 in preventing the recurrence of hepatocellular carcinoma after curative treatment: a meta-analysis of randomized controlled trials. BMC Gastroenterol 2012;12:170. [PMID: 23191943 DOI: 10.1186/1471-230X-12-170] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
20 Wang X, Li L, Huang Y, Wei Q. Calcineurin subunit B upregulates β-interferon production by phosphorylation of interferon regulatory factor 3 via Toll-like receptor 4. Cancer Sci 2012;103:515-21. [PMID: 22118374 DOI: 10.1111/j.1349-7006.2011.02160.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
21 Di Maio M, De Maio E, Perrone F, Pignata S, Daniele B. Hepatocellular Carcinoma: Systemic Treatments. Journal of Clinical Gastroenterology 2002;35:S109-14. [DOI: 10.1097/00004836-200211002-00007] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 2.2] [Reference Citation Analysis]
22 Aguayo A, Patt YZ. Nonsurgical Treatment of Hepatocellular Carcinoma. Clinics in Liver Disease 2001;5:175-89. [DOI: 10.1016/s1089-3261(05)70160-4] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
23 Adachi E, Maehara S, Tsujita E, Taguchi K, Aishima S, Rikimaru T, Yamashita Y, Tanaka S. Clinicopathologic risk factors for recurrence after a curative hepatic resection for hepatocellular carcinoma. Surgery. 2002;131:S148-S152. [PMID: 11821802 DOI: 10.1067/msy.2002.119496] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
24 Pang Q, Qu K, Bi JB, Liu SS, Zhang JY, Song SD, Lin T, Xu XS, Wan Y, Tai MH, Liu HC, Dong YF, Liu C. Thrombocytopenia for prediction of hepatocellular carcinoma recurrence: Systematic review and meta-analysis. World J Gastroenterol 2015;21:7895-906. [PMID: 26167090 DOI: 10.3748/wjg.v21.i25.7895] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
25 Lin SM, Chu CM. Secondary prevention of hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol Hepatol 2005;20:1475-7. [PMID: 16174061 DOI: 10.1111/j.1440-1746.2005.04016.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
26 Iida H, Osaki R, Fujimoto T, Maehira H, Mori H, Kitamura N, Andoh A, Tani M. Interval between hepatocellular carcinoma treatment and interferon-free direct-acting antiviral agents against hepatitis C is necessary to suppress tumor recurrence. Mol Clin Oncol 2019;11:99-105. [PMID: 31289685 DOI: 10.3892/mco.2019.1847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Xia W, Li D, Wang G, Ni J, Zhuang J, Ha M, Wang J, Ye Y. Small activating RNA upregulates NIS expression: promising potential for hepatocellular carcinoma endoradiotherapy. Cancer Gene Ther 2016;23:333-40. [PMID: 27608773 DOI: 10.1038/cgt.2016.36] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
28 Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, Zhang BH, Qian YB, Wu ZQ, Fan J. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006;132:458-465. [PMID: 16557381 DOI: 10.1007/s00432-006-0091-y] [Cited by in Crossref: 156] [Cited by in F6Publishing: 135] [Article Influence: 10.4] [Reference Citation Analysis]
29 Kim MN, Han KH, Ahn SH. Prevention of hepatocellular carcinoma: beyond hepatitis B vaccination. Semin Oncol. 2015;42:316-328. [PMID: 25843736 DOI: 10.1053/j.seminoncol.2014.12.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
30 Ogasawara S, Yano H, Momosaki S, Akiba J, Nishida N, Kojiro S, Moriya F, Ishizaki H, Kuratomi K, Kojiro M. Growth inhibitory effects of IFN-beta on human liver cancer cells in vitro and in vivo. J Interferon Cytokine Res 2007;27:507-16. [PMID: 17572015 DOI: 10.1089/jir.2007.0183] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
31 Hsu CS, Chao YC, Lin HH, Chen DS, Kao JH. Systematic Review: Impact of Interferon-based Therapy on HCV-related Hepatocellular Carcinoma. Sci Rep. 2015;5:9954. [PMID: 25963067 DOI: 10.1038/srep09954] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
32 Hiramatsu N, Oze T, Takehara T. Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy. Hepatol Res. 2015;45:152-161. [PMID: 25052449 DOI: 10.1111/hepr.12393] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 6.6] [Reference Citation Analysis]
33 Stribling R, Sussman N, Vierling JM. Treatment of hepatitis C infection. Gastroenterol Clin North Am. 2006;35:463-486. [PMID: 16880075 DOI: 10.1016/j.gtc.2006.05.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
34 Blum HE. Treatment of hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 2005;19:129-45. [DOI: 10.1016/j.bpg.2004.11.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
35 Yamazaki K, Suzuki K, Ohkoshi S, Yano M, Kurita S, Aoki YH, Toba K, Takamura MA, Yamagiwa S, Matsuda Y. Temporal treatment with interferon-beta prevents hepatocellular carcinoma in hepatitis B virus X gene transgenic mice. J Hepatol. 2008;48:255-265. [PMID: 18083266 DOI: 10.1016/j.jhep.2007.09.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
36 Yanaga K, Okudaira S, Kanematsu T, Marsh JW. Hepatic Resection for Hepatocellular Carcinoma. In: Carr BI, editor. Hepatocellular Cancer. Totowa: Humana Press; 2005. pp. 185-98. [DOI: 10.1007/978-1-59259-844-1_9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
37 Radaeva S, Jaruga B, Hong F, Kim W, Fan S, Cai H, Strom S, Liu Y, El–assal O, Gao B. Interferon-α activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology 2002;122:1020-34. [DOI: 10.1053/gast.2002.32388] [Cited by in Crossref: 96] [Cited by in F6Publishing: 99] [Article Influence: 5.1] [Reference Citation Analysis]
38 Ryu T, Takami Y, Wada Y, Tateishi M, Matsushima H, Yoshitomi M, Mikagi K, Saitsu H. Effect of achieving sustained virological response before hepatitis C virus-related hepatocellular carcinoma occurrence on survival and recurrence after curative surgical microwave ablation. Hepatol Int 2018;12:149-57. [DOI: 10.1007/s12072-018-9851-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
39 Sun P, Yang X, He RQ, Hu QG, Song ZF, Xiong J, Zheng QC. Antiviral therapy after curative treatment of hepatitis B/C virus-related hepatocellular carcinoma: A systematic review of randomized trials. Hepatol Res. 2014;44:259-269. [PMID: 23607290 DOI: 10.1111/hepr.12115] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
40 Kanogawa N, Ogasawara S, Chiba T, Saito T, Motoyama T, Suzuki E, Ooka Y, Tawada A, Kanda T, Mikami S. Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. J Gastroenterol Hepatol. 2015;30:1197-1204. [PMID: 25682720 DOI: 10.1111/jgh.12925] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
41 Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev. 2009;CD001199. [PMID: 19160192 DOI: 10.1002/14651858.cd001199] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
42 Yoshiji H, Kuriyama S, Fukui H. Perindopril: possible use in cancer therapy: . Anti-Cancer Drugs 2002;13:221-8. [DOI: 10.1097/00001813-200203000-00003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
43 Guo Z, Zhong JH, Jiang JH, Zhang J, Xiang BD, Li LQ. Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis. Ann Surg Oncol. 2014;21:3069-3076. [PMID: 24728740 DOI: 10.1245/s10434-014-3704-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
44 Tabor E. Interferon for preventing and treating hepatocellular carcinoma associated with the hepatitis B and C viruses. Dig Liver Dis 2003;35:297-305. [PMID: 12846400 DOI: 10.1016/s1590-8658(03)00071-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
45 Shindoh J, Hasegawa K, Matsuyama Y, Inoue Y, Ishizawa T, Aoki T, Sakamoto Y, Sugawara Y, Makuuchi M, Kokudo N. Low hepatitis C viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis C virus. J Clin Oncol. 2013;31:766-773. [PMID: 23129744 DOI: 10.1200/jco.2012.44.3234] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
46 Heathcote EJ. Prevention of hepatitis C virus–related hepatocellular carcinoma. Gastroenterology 2004;127:S294-302. [DOI: 10.1053/j.gastro.2004.09.044] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 4.2] [Reference Citation Analysis]
47 Sakae M, Kubo S, Takemura S, Sakata C, Uenishi T, Kodai S, Shinkawa H, Urata Y, Ohata K, Kaneda K, Nishioka T, Nozawa A, Suehiro S. Effect of interferon therapy on first and second recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Hepatol Res 2012;42:564-73. [PMID: 22257119 DOI: 10.1111/j.1872-034X.2011.00959.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
48 Zhong J, Ma L, Li L. Postoperative therapy options for hepatocellular carcinoma. Scandinavian Journal of Gastroenterology 2014;49:649-61. [DOI: 10.3109/00365521.2014.905626] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
49 Sawada Y, Yoshikawa T, Ofuji K, Yoshimura M, Tsuchiya N, Takahashi M, Nobuoka D, Gotohda N, Takahashi S, Kato Y, Konishi M, Kinoshita T, Ikeda M, Nakachi K, Yamazaki N, Mizuno S, Takayama T, Yamao K, Uesaka K, Furuse J, Endo I, Nakatsura T. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. Oncoimmunology. 2016;5:e1129483. [PMID: 27467945 DOI: 10.1080/2162402x.2015.1129483] [Cited by in Crossref: 77] [Cited by in F6Publishing: 45] [Article Influence: 15.4] [Reference Citation Analysis]
50 Jiang S, Liu Y, Wang L, Duan C, Liu M. A meta-analysis and systematic review: adjuvant interferon therapy for patients with viral hepatitis-related hepatocellular carcinoma. World J Surg Oncol. 2013;11:240. [PMID: 24060218 DOI: 10.1186/1477-7819-11-240] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
51 Kudo M, Sakaguchi Y, Chung H, Hatanaka K, Hagiwara S, Ishikawa E, Takahashi S, Kitai S, Inoue T, Minami Y. Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology. 2007;72 Suppl 1:132-138. [PMID: 18087194 DOI: 10.1159/000111719] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
52 Li N, Lai EC, Shi J, Guo WX, Xue J, Huang B, Lau WY, Wu MC, Cheng SQ. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol. 2010;17:179-185. [PMID: 19727956 DOI: 10.1245/s10434-009-0694-z] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 6.3] [Reference Citation Analysis]
53 Kim BK, Han K, Ahn SH. Prevention of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection. Oncology 2011;81:41-9. [DOI: 10.1159/000333258] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
54 Kudo M. Adjuvant therapy after curative treatment for hepatocellular carcinoma. Oncology. 2011;81 Suppl 1:50-55. [PMID: 22212936 DOI: 10.1159/000333259] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
55 Hsu Y, Wu C, Lin J. Hepatitis C Virus Infection, Antiviral Therapy, and Risk of Hepatocellular Carcinoma. Seminars in Oncology 2015;42:329-38. [DOI: 10.1053/j.seminoncol.2014.12.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
56 Hirokawa F, Hayashi M, Asakuma M, Shimizu T, Inoue Y, Uchiyama K. Risk factors and patterns of early recurrence after curative hepatectomy for hepatocellular carcinoma. Surg Oncol. 2016;25:24-29. [PMID: 26979637 DOI: 10.1016/j.suronc.2015.12.002] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 8.2] [Reference Citation Analysis]
57 Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, Lin DY, Liaw YF. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer. 2004;100:376-382. [PMID: 14716774 DOI: 10.1002/cncr.20004] [Cited by in Crossref: 90] [Cited by in F6Publishing: 88] [Article Influence: 5.3] [Reference Citation Analysis]
58 Zhang CH, Xu GL, Jia WD, Ge YS. Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Cancer. 2009;124:2982-2988. [PMID: 19296539 DOI: 10.1002/ijc.24311] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
59 Tomimaru Y, Nagano H, Eguchi H, Kobayashi S, Marubashi S, Wada H, Tanemura M, Umeshita K, Hiramatsu N, Takehara T, Doki Y, Mori M. Effects of preceding interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol 2010;102:308-14. [DOI: 10.1002/jso.21633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
60 Perry JF, Strasser SI, George J, Farrell GC, Mccaughan GW. Pharmacotherapy of hepatocellular carcinoma. Expert Opinion on Pharmacotherapy 2005;4:2175-85. [DOI: 10.1517/14656566.4.12.2175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
61 Zhong C, Guo RP, Li JQ, Shi M, Wei W, Chen MS, Zhang YQ. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009;135:1437-1445. [PMID: 19408012 DOI: 10.1007/s00432-009-0588-2] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 6.1] [Reference Citation Analysis]
62 Shimomura S, Ikeda N, Saito M, Ishii A, Takashima T, Sakai Y, Yoshikawa S, Aizawa N, Tanaka H, Iwata Y, Enomoto H, Imanishi H, Yamamoto T, Jomura H, Nakamura H, Iijima H, Nishiguchi S. Long-term interferon therapy after radiofrequency ablation is effective in treating patients with HCV-associated hepatocellular carcinoma. Hepatol Int 2010;5:559-66. [PMID: 21442053 DOI: 10.1007/s12072-010-9214-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
63 Uenishi T, Nagano H, Marubashi S, Hayashi M, Hirokawa F, Kaibori M, Matsui K, Kubo S. The long-term outcomes after curative resection for mass-forming intrahepatic cholangiocarcinoma associated with hepatitis C viral infection: a multicenter analysis by Osaka Hepatic Surgery Study Group. J Surg Oncol. 2014;110:176-181. [PMID: 24760391 DOI: 10.1002/jso.23611] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
64 Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, Fan ST, Wong J. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg. 2007;245:831-842. [PMID: 17522506 DOI: 10.1097/01.sla.0000245829.00977.45] [Cited by in Crossref: 144] [Cited by in F6Publishing: 133] [Article Influence: 10.3] [Reference Citation Analysis]
65 Tanimoto Y, Tashiro H, Aikata H, Amano H, Oshita A, Kobayashi T, Kuroda S, Tazawa H, Takahashi S, Itamoto T. Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection. Ann Surg Oncol. 2012;19:418-425. [PMID: 21710324 DOI: 10.1245/s10434-011-1866-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
66 Wang J, He XD, Yao N, Liang WJ, Zhang YC. A meta-analysis of adjuvant therapy after potentially curative treatment for hepatocellular carcinoma. Can J Gastroenterol 2013;27:351-63. [PMID: 23781519 DOI: 10.1155/2013/417894] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
67 Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. J Med Virol. 2007;79:1485-1490. [PMID: 17705189 DOI: 10.1002/jmv.20925] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
68 Okuno M, Kojima S, Moriwaki H. Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives. J Gastroenterol Hepatol. 2001;16:1329-1335. [PMID: 11851828 DOI: 10.1046/j.1440-1746.2001.02634.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
69 Arase Y, Ikeda K, Tsubota A, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Hosaka T, Sezaki H, Kobayashi M, Kumada H. Interferon Therapy for 2 Years or Longer Reduces the Incidence of Hepatocarcinogenesis in Patients with Chronic Hepatitis C Viral Infection. Intervirology 2004;47:355-61. [DOI: 10.1159/000080880] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
70 Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol. 2010;52:889-894. [PMID: 20395009 DOI: 10.1016/j.jhep.2009.12.041] [Cited by in Crossref: 99] [Cited by in F6Publishing: 96] [Article Influence: 9.0] [Reference Citation Analysis]
71 Farrell G, Fan J. Prevention of Hepatocellular Carcinoma. In: Al Knawy B, Reddy K, Bolondi L, editors. Hepatocellular Carcinoma. CRC Press; 2009. pp. 36-61. [DOI: 10.3109/9780203092880-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
72 Kashiwagi K, Furusyo N, Kubo N, Nakashima H, Nomura H, Kashiwagi S, Hayashi J. A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development. J Infect Chemother 2003;9:333-40. [PMID: 14691655 DOI: 10.1007/s10156-003-0271-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
73 Huo T, Lin H. Metastatic hepatocellular carcinoma: when, how, where and so what?: Editorial. Liver International 2008;28:1183-5. [DOI: 10.1111/j.1478-3231.2008.01863.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
74 Du Y, Su T, Ding Y, Cao G. Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation. Hepat Mon. 2012;12:e6031. [PMID: 23166535 DOI: 10.5812/hepatmon.6031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
75 Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Ohgi K, Uesaka K. The Achievement of a Sustained Virological Response Either Before or After Hepatectomy Improves the Prognosis of Patients with Primary Hepatitis C Virus-Related Hepatocellular Carcinoma. Ann Surg Oncol 2019;26:4566-75. [PMID: 31602577 DOI: 10.1245/s10434-019-07911-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
76 Sun H, Zhang W. Re: Interferon: The Magic Bullet to Prevent Hepatocellular Carcinoma Recurrence After Resection? Annals of Surgery 2008;247:900. [DOI: 10.1097/sla.0b013e31816ff75c] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
77 Ooka Y, Miho K, Shuntaro O, Nakamura M, Ogasawara S, Suzuki E, Yasui S, Chiba T, Arai M, Kanda T, Maruyama H, Yokosuka O, Kato N, Mochizuki H, Omata M. Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection. Hepatol Int 2018;12:523-30. [PMID: 30242733 DOI: 10.1007/s12072-018-9895-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
78 Izumi N, Asahina Y, Tsuchiya K, Kurosaki M, Nakanishi H, Kitamura T, Uchihara M, Miyake S. Repeated radiofrequency ablation for the distant recurrence in the liver in patients with chronic hepatitis C virus infection achieving long-term survival. Hepatology Research 2007;37:S254-63. [DOI: 10.1111/j.1872-034x.2007.00193.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
79 Utsunomiya T, Shimada M, Imura S, Morine Y, Ikemoto T, Mori M. Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J Gastroenterol. 2010;45:146-152. [PMID: 19997856 DOI: 10.1007/s00535-009-0164-1] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 4.8] [Reference Citation Analysis]
80 Chen LT, Chen MF, Li LA, Lee PH, Jeng LB, Lin DY, Wu CC, Mok KT, Chen CL, Lee WC, Chau GY, Chen YS, Lui WY, Hsiao CF, Whang-Peng J, Chen PJ; Disease Committee of Adjuvant Therapy for Postoperative Hepatocellular Carcinoma, Taiwan Cooperative Oncology Group, National Health Research Institutes, Zhunan, Taiwan. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg. 2012;255:8-17. [PMID: 22104564 DOI: 10.1097/sla.0b013e3182363ff9] [Cited by in Crossref: 78] [Cited by in F6Publishing: 34] [Article Influence: 8.7] [Reference Citation Analysis]
81 Okuwaki Y, Nakazawa T, Kokubu S, Hidaka H, Tanaka Y, Takada J, Watanabe M, Shibuya A, Minamino T, Saigenji K. Repeat Radiofrequency Ablation Provides Survival Benefit in Patients With Intrahepatic Distant Recurrence of Hepatocellular Carcinoma. Am J Gastroenterol 2009;104:2747-53. [DOI: 10.1038/ajg.2009.414] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
82 Qu LS, Zhang HF. Significance of viral status on prognosis of hepatitis B-related hepatocellular carcinoma after curative resection in East Asia. Hepatol Res 2016;46:40-9. [PMID: 25858122 DOI: 10.1111/hepr.12523] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
83 Qin LX, Tang ZY. The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol. 2002;8:193-199. [PMID: 11925590 DOI: 10.3748/wjg.v8.i2.193] [Cited by in CrossRef: 123] [Cited by in F6Publishing: 113] [Article Influence: 6.5] [Reference Citation Analysis]
84 Kew MC. Prevention of hepatocellular carcinoma. HPB (Oxford) 2005;7:16-25. [PMID: 18333157 DOI: 10.1080/13651820410024030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
85 Inamura K, Matsuzaki Y, Uematsu N, Honda A, Tanaka N, Uchida K. Rapid inhibition of MAPK signaling and anti-proliferation effect via JAK/STAT signaling by interferon-α in hepatocellular carcinoma cell lines. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2005;1745:401-10. [DOI: 10.1016/j.bbamcr.2005.06.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
86 Walzer N, Kulik LM. Hepatocellular carcinoma: latest developments. Curr Opin Gastroenterol 2008;24:312-9. [PMID: 18408459 DOI: 10.1097/MOG.0b013e3282fafef3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
87 Jang JW. Management of viral hepatitis in patients with hepatocellular carcinoma. J Korean Med Assoc 2013;56:1001. [DOI: 10.5124/jkma.2013.56.11.1001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
88 Kohli V, Singhal A, Elliott L, Jalil S. Antiviral therapy for recurrent hepatitis C reduces recurrence of hepatocellular carcinoma following liver transplantation. Transpl Int. 2012;25:192-200. [PMID: 22151471 DOI: 10.1111/j.1432-2277.2011.01396.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
89 Li W, Cheung M. Recurrence and survival for hepatocellular carcinoma after curative resection: Tertiary centre experience. Surgical Practice 2008;12:45-50. [DOI: 10.1111/j.1744-1633.2008.00400.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
90 Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer. 2004;40:1474-1484. [PMID: 15196530 DOI: 10.1016/j.ejca.2004.02.027] [Cited by in Crossref: 134] [Cited by in F6Publishing: 103] [Article Influence: 7.9] [Reference Citation Analysis]
91 Lodato F, Mazzella G, Festi D, Azzaroli F, Colecchia A, Roda E. Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol 2006;12:7239-49. [PMID: 17143937 DOI: 10.3748/wjg.v12.i45.7239] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 49] [Article Influence: 4.8] [Reference Citation Analysis]
92 Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, Imazu H, Yanase K, Kuriyama S, Fukui H. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J Hepatol. 2002;37:22-30. [PMID: 12076858 DOI: 10.1016/s0168-8278(02)00104-6] [Cited by in Crossref: 59] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
93 Ishikawa T. Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 2013;19:8861-8866. [PMID: 24379608 DOI: 10.3748/wjg.v19.i47.8861] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
94 Cabibbo G, Petta S, Barbàra M, Missale G, Virdone R, Caturelli E, Piscaglia F, Morisco F, Colecchia A, Farinati F, Giannini E, Trevisani F, Craxì A, Colombo M, Cammà C; ITA.LI.CA study group. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. Liver Int 2017;37:1157-66. [PMID: 28061016 DOI: 10.1111/liv.13357] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 11.5] [Reference Citation Analysis]
95 Li S, Saviano A, Erstad DJ, Hoshida Y, Fuchs BC, Baumert T, Tanabe KK. Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. J Clin Med 2020;9:E3817. [PMID: 33255794 DOI: 10.3390/jcm9123817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
96 Greten TF, Manns MP, Korangy F. Immunotherapy of hepatocellular carcinoma. J Hepatol. 2006;45:868-878. [PMID: 17046096 DOI: 10.1016/j.jhep.2006.09.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 3.5] [Reference Citation Analysis]
97 Nishiguchi S, Tamori A, Kubo S. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology. 2005;48:71-75. [PMID: 15785093 DOI: 10.1159/000082098] [Cited by in Crossref: 40] [Cited by in F6Publishing: 48] [Article Influence: 2.5] [Reference Citation Analysis]
98 Yamazaki S, Takayama T. Surgical treatment of hepatocellular carcinoma: evidence-based outcomes. World J Gastroenterol. 2008;14:685-692. [PMID: 18205256 DOI: 10.3748/wjg.14.685] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
99 Koff RS. Disease Management Programs for Hepatitis C: A Team Approach to Setting Goals. Disease Management and Health Outcomes 2001;9:431-9. [DOI: 10.2165/00115677-200109080-00003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
100 Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev. 2009;CD001199. [PMID: 19160192 DOI: 10.1002/14651858.cd001199.pub2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
101 Poon RT, Ng IO, Lau C, Yu WC, Yang ZF, Fan ST, Wong J. Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol. 2002;20:1775-1785. [PMID: 11919234 DOI: 10.1200/jco.2002.07.089] [Cited by in Crossref: 198] [Cited by in F6Publishing: 82] [Article Influence: 10.4] [Reference Citation Analysis]
102 Zhuang L, Zeng X, Yang Z, Meng Z. Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One. 2013;8:e61361. [PMID: 24069133 DOI: 10.1371/journal.pone.0061361] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
103 Nguyen MH, Keeffe EB. General management. Best Practice & Research Clinical Gastroenterology 2005;19:161-74. [DOI: 10.1016/j.bpg.2004.11.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
104 Hosaka T, Ikeda K, Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Akuta N, Suzuki F, Suzuki Y. Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma. Liver Int. 2009;29:736-742. [PMID: 19018978 DOI: 10.1111/j.1478-3231.2008.01901.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
105 Shimomura S, Nishiguchi S. Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infection. Hepatol Res 2012;42:22-32. [PMID: 21951512 DOI: 10.1111/j.1872-034X.2011.00889.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
106 Bricard G, Bouzourene H, Martinet O, Rimoldi D, Halkic N, Gillet M, Chaubert P, Macdonald HR, Romero P, Cerottini J, Speiser DE. Naturally Acquired MAGE-A10- and SSX-2-Specific CD8 + T Cell Responses in Patients with Hepatocellular Carcinoma. J Immunol 2005;174:1709-16. [DOI: 10.4049/jimmunol.174.3.1709] [Cited by in Crossref: 70] [Cited by in F6Publishing: 58] [Article Influence: 4.4] [Reference Citation Analysis]
107 Kusano H, Ogasawara S, Akiba J, Nakayama M, Ueda K, Yano H. Antiproliferative effects of sorafenib and pegylated IFN‑α2b on human liver cancer cells in vitro and in vivo. Int J Oncol 2013;42:1897-903. [PMID: 23588838 DOI: 10.3892/ijo.2013.1904] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
108 Hino K, Kitase A, Satoh Y, Fujiwara D, Yamaguchi Y, Korenaga M, Shingai Y, Konishi T, Yamashita S, Uchida K. Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. J Viral Hepat. 2002;9:370-376. [PMID: 12225332 DOI: 10.1046/j.1365-2893.2002.00366.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
109 Borbath I, Leclercq I, Moulin P, Sempoux C, Horsmans Y. The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver. Eur J Cancer. 2007;43:1755-1763. [PMID: 17582756 DOI: 10.1016/j.ejca.2007.05.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
110 Koda M, Tanaka S, Takemura S, Shinkawa H, Kinoshita M, Hamano G, Ito T, Kawada N, Shibata T, Kubo S. Long-Term Prognostic Factors after Hepatic Resection for Hepatitis C Virus-Related Hepatocellular Carcinoma, with a Special Reference to Viral Status. Liver Cancer 2018;7:261-76. [PMID: 30319984 DOI: 10.1159/000486902] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
111 Izumi N. Prediction and prevention of intrahepatic recurrence of hepatocellular carcinoma. Hepatol Res. 2012;42:226-232. [PMID: 22181559 DOI: 10.1111/j.1872-034x.2011.00922.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
112 Merle P, Chevallier M, Levy R, Maisonnas M, Terradillos O, Ahmed SNS, Trépo C, Buendia MA, Vitvitski-Trépo L. Preliminary results of interferon-alpha therapy on woodchuck hepatitis virus-induced hepatocarcinogenesis: possible benefit in female transgenic mice. J Hepatol 2001;34:562-9. [PMID: 11394656 DOI: 10.1016/s0168-8278(00)00054-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
113 Yamashita Y, Tsuijita E, Takeishi K, Ishida T, Ikegami T, Ezaki T, Maeda T, Utsunomiya T, Nagasue N, Shirabe K. Trends in surgical results of hepatic resection for hepatocellular carcinoma: 1,000 consecutive cases over 20 years in a single institution. Am J Surg. 2014;207:890-896. [PMID: 24144344 DOI: 10.1016/j.amjsurg.2013.07.028] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
114 Masuzaki R, Yoshida H, Omata M. Does chemotherapy prevent HCV-related hepatocellular carcinoma? Pros. Digestive and Liver Disease 2010;42:S281-6. [DOI: 10.1016/s1590-8658(10)60517-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
115 Sun HC, Tang ZY. Preventive treatments for recurrence after curative resection of hepatocellular carcinoma--a literature review of randomized control trials. World J Gastroenterol 2003;9:635-40. [PMID: 12679900 DOI: 10.3748/wjg.v9.i4.635] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 44] [Article Influence: 2.7] [Reference Citation Analysis]
116 Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang L, Zhou J, Qiu SJ, Li Y. A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:187-196. [PMID: 14685850 DOI: 10.1007/s00432-003-0511-1] [Cited by in Crossref: 326] [Cited by in F6Publishing: 298] [Article Influence: 18.1] [Reference Citation Analysis]
117 Prenner S, Kulik L. HCC: Where Does HCV Therapy Play a Role? Curr Hepatology Rep 2016;15:17-25. [DOI: 10.1007/s11901-016-0292-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
118 Takami T, Yamasaki T, Saeki I, Matsumoto T, Suehiro Y, Sakaida I. Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function. World J Gastroenterol 2016;22:7252-63. [PMID: 27621572 DOI: 10.3748/wjg.v22.i32.7252] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
119 Borbath I, Leclercq IA, Abarca-Quinones J, Desaeger C, Lebrun V, Moulin P, Sempoux C, Horsmans Y. Inhibition of early preneoplastic events in the rat liver by the somatostatin analog lanreotide. Cancer Sci 2007;98:1831-9. [PMID: 17900309 DOI: 10.1111/j.1349-7006.2007.00626.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
120 Gao Q, Shi Y, Wang X, Zhou J, Qiu S, Fan J. Translational medicine in hepatocellular carcinoma. Front Med. 2012;6:122-133. [PMID: 22573220 DOI: 10.1007/s11684-012-0193-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
121 Vu NB, Nguyen TT, Tran LC, Do CD, Nguyen BH, Phan NK, Pham PV. Doxorubicin and 5-fluorouracil resistant hepatic cancer cells demonstrate stem-like properties. Cytotechnology. 2013;65:491-503. [PMID: 23104270 DOI: 10.1007/s10616-012-9511-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
122 Nishiguchi S, Kubo S. Randomized Trial of Post-Operative Interferon Therapy After Resection of Hepatitis C Virus-Related Hepatocellular Carcinoma and Long-Term Outcome. In: Omata M, Okita K, editors. Therapy for Viral Hepatitis and Prevention of Hepatocellular Carcinoma. Tokyo: Springer Japan; 2004. pp. 209-18. [DOI: 10.1007/978-4-431-53977-3_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
123 Surveillance group. ; Diagnosis group; Staging group; Surgery group; Local ablation group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2018;117:381-403. [PMID: 29074347 DOI: 10.1016/j.jfma.2017.09.007] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 11.8] [Reference Citation Analysis]
124 Craxì A, Cammà C. Prevention of hepatocellular carcinoma. Clin Liver Dis 2005;9:329-46, viii. [PMID: 15831277 DOI: 10.1016/j.cld.2004.12.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
125 Wirth TC, Manns MP. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. Ann Oncol 2016;27:1467-74. [PMID: 27226385 DOI: 10.1093/annonc/mdw219] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
126 Shirabe K, Takeishi K, Taketomi A, Uchiyama H, Kayashima H, Maehara Y. Improvement of Long-Term Outcomes in Hepatitis C Virus Antibody–Positive Patients with Hepatocellular Carcinoma after Hepatectomy in the Modern Era. World J Surg 2011;35:1072-84. [DOI: 10.1007/s00268-011-1013-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
127 Zhong JH, Li H, Li LQ, You XM, Zhang Y, Zhao YN, Liu JY, Xiang BD, Wu GB. Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials. Eur J Surg Oncol. 2012;38:286-295. [PMID: 22281155 DOI: 10.1016/j.ejso.2012.01.006] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
128 Ahn SH, Lee HW, Kim YS, Kim JK, Han KH, Chon CY, Moon YM. Recombinant interferon-Beta-1alpha plus ribavirin for the treatment of chronic HCV infection: a prospective, randomized, comparative pilot study. Gut Liver 2009;3:20-5. [PMID: 20479896 DOI: 10.5009/gnl.2009.3.1.20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
129 Kainuma M, Ogata N, Kogure T, Kohta K, Hattori N, Mitsuma T, Terasawa K. The efficacy of a herbal medicine (Mao-to) in combination with intravenous natural interferon-beta for patients with chronic hepatitis C, genotype 1b and high viral load: a pilot study. Phytomedicine. 2002;9:365-372. [PMID: 12222653 DOI: 10.1078/09447110260571571] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
130 Matsumoto K, Okano J, Murawaki Y. Differential effects of interferon alpha-2b and beta on the signaling pathways in human liver cancer cells. J Gastroenterol 2005;40:722-32. [DOI: 10.1007/s00535-005-1616-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
131 Jin Y, Lee J, Lee OH, Chung HJ, Kim YS, Lee JI, Cho SG, Jeon YS, Lee KY, Ahn S, Shin WY. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion: Recurrent hepatocellular carcinoma. J Gastroenterol Hepatol 2014;29:1056-64. [DOI: 10.1111/jgh.12507] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
132 Ng IO, Poon RT, Shek TW, Fan ST. Clinicopathologic and Prognostic Significance of the Histologic Activity of Noncancerous Liver Tissue in Hepatitis B Virus–Associated Hepatocellular Carcinoma. Am J Clin Pathol 2002;117:411-8. [DOI: 10.1309/4231-rcvb-wk8x-r1jk] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
133 Zhao H, Wang J, Han Y, Huang Z, Ying J, Bi X, Zhao J, Fang Y, Zhou H, Zhou J, Li Z, Zhang Y, Yang X, Yan T, Wang L, Torbenson MS, Cai J. ARID2: a new tumor suppressor gene in hepatocellular carcinoma. Oncotarget 2011;2:886-91. [PMID: 22095441 DOI: 10.18632/oncotarget.355] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
134 Irie M, Homma S, Komita H, Zeniya M, Kufe D, Ohno T, Toda G. Inhibition of spontaneous development of liver tumors by inoculation with dendritic cells loaded with hepatocellular carcinoma cells in C3H/HeNCRJ mice. Int J Cancer 2004;111:238-45. [DOI: 10.1002/ijc.20247] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
135 Mallat DB, El-Serag HB. Interferon: benefit beyond hepatitis therapy? Am J Gastroenterol 2001;96:3435-6. [PMID: 11774964 DOI: 10.1111/j.1572-0241.2001.05371.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
136 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-474. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in Crossref: 684] [Cited by in F6Publishing: 655] [Article Influence: 62.2] [Reference Citation Analysis]
137 Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359:1995-2004. [PMID: 18923165 DOI: 10.1056/nejmoa0804525] [Cited by in Crossref: 886] [Cited by in F6Publishing: 470] [Article Influence: 68.2] [Reference Citation Analysis]
138 Everson GT. Maintenance interferon for chronic hepatitis C: More issues than answers? Hepatology 2000;32:436-8. [DOI: 10.1053/jhep.2000.16216] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
139 Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev. 2009;CD001199. [PMID: 19160192 DOI: 10.1002/14651858.cd001199.pub2.] [Reference Citation Analysis]
140 Prieto J, Qian C, Sangro B, Melero I, Mazzolini G. Biologic therapy of liver tumors. Surg Clin North Am. 2004;84:673-696. [PMID: 15062668 DOI: 10.1016/s0039-6109(03)00230-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
141 Wen T, Jin C, Facciorusso A, Donadon M, Han HS, Mao Y, Dai C, Cheng S, Zhang B, Peng B, Du S, Jia C, Xu F, Shi J, Sun J, Zhu P, Nara S, Millis JM; MDT of West China Hospital*. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. Hepatobiliary Surg Nutr 2018;7:353-71. [PMID: 30498711 DOI: 10.21037/hbsn.2018.08.01] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
142 Sun H, Tang Z, Ma Z, Qin L, Wang L, Ye Q, Fan J, Wu Z, Zhou X. The prognostic factor for outcome following second resection for intrahepatic recurrence of hepatocellular carcinoma with a hepatitis B virus infection background. J Cancer Res Clin Oncol 2005;131:284-8. [DOI: 10.1007/s00432-004-0645-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
143 Kawaoka T, Aikata H, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Tashiro H, Ohdan H, Chayama K. IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma: PEGIFN/RBV after treatment for HCC. Journal of Viral Hepatitis 2011;18:e550-60. [DOI: 10.1111/j.1365-2893.2011.01468.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
144 Zein CO, Zein NN. Advances in therapy for hepatitis C infection. Microbes Infect. 2002;4:1237-1246. [PMID: 12467765 DOI: 10.1016/s1286-4579(02)01651-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
145 Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Müllhaupt B, Clavien PA. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg. 2009;96:975-981. [PMID: 19672926 DOI: 10.1002/bjs.6731] [Cited by in Crossref: 108] [Cited by in F6Publishing: 102] [Article Influence: 9.0] [Reference Citation Analysis]
146 Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y, Kobayashi M, Kumada H. Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C. J Med Virol 2007;79:1095-102. [PMID: 17597485 DOI: 10.1002/jmv.20866] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
147 Clavien PA. Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection? Ann Surg. 2007;245:843-845. [PMID: 17522507 DOI: 10.1097/sla.0b013e31805d0788] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
148 Taieb J, Barbare J, Rougier P. Medical treatments for hepatocellular carcinoma (HCC): what’s next? Annals of Oncology 2006;17:x308-14. [DOI: 10.1093/annonc/mdl279] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
149 Korean Liver Cancer Study Group and National Cancer Center, Korea. [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol. 2009;15:391-423. [PMID: 19783891 DOI: 10.3350/kjhep.2009.15.3.391] [Cited by in Crossref: 182] [Cited by in F6Publishing: 173] [Article Influence: 16.5] [Reference Citation Analysis]
150 Okita K, Izumi N, Ikeda K, Osaki Y, Numata K, Ikeda M, Kokudo N, Imanaka K, Nishiguchi S, Kondo S. Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial. J Gastroenterol. 2015;50:667-674. [PMID: 25209978 DOI: 10.1007/s00535-014-0996-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
151 Kornek M, Lukacs-Kornek V, Limmer A, Raskopf E, Becker U, Klöckner M, Sauerbruch T, Schmitz V. 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)-formulated, immune-stimulatory vascular endothelial growth factor a small interfering RNA (siRNA) increases antitumoral efficacy in murine orthotopic hepatocellular carcinoma with liver fibrosis. Mol Med 2008;14:365-73. [PMID: 18392108 DOI: 10.2119/2008-00003.Kornek] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
152 Yamashita Y, Shirabe K, Toshima T, Tsuijita E, Takeishi K, Harimoto N, Ikegami T, Yoshizumi T, Ikeda T, Soejima Y, Maehara Y. Risk factors for recurrence after curative resection of hepatitis C-related hepatocellular carcinoma in patients without postoperative interferon therapy. Hepatol Res 2013;43:1313-20. [PMID: 23534348 DOI: 10.1111/hepr.12091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
153 Sun P, Dong X, Cheng X, Hu Q, Zheng Q. Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. PLoS One. 2014;9:e102761. [PMID: 25058587 DOI: 10.1371/journal.pone.0102761] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
154 Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. The Lancet Oncology 2002;3:593-603. [DOI: 10.1016/s1470-2045(02)00873-2] [Cited by in Crossref: 169] [Cited by in F6Publishing: 58] [Article Influence: 8.9] [Reference Citation Analysis]
155 Miao RY, Zhao HT, Yang HY, Mao YL, Lu X, Zhao Y, Liu CN, Zhong SX, Sang XT, Huang JF. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J Gastroenterol. 2010;16:2931-2942. [PMID: 20556841 DOI: 10.3748/wjg.v16.i23.2931] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
156 Hagihara H, Nouso K, Kobayashi Y, Iwasaki Y, Nakamura S, Kuwaki K, Toshimori J, Miyatake H, Ohnishi H, Shiraha H, Yamamoto K. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Clin Oncol 2011;16:210-20. [DOI: 10.1007/s10147-010-0150-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
157 Forner A, Roayaie S. Clinical research in hepatocellular carcinoma: study design and endpoints. J Hepatol. 2009;50:850-853. [PMID: 19329214 DOI: 10.1016/j.jhep.2009.02.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
158 Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, Llovet JM, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) 2009;132:272-87. [PMID: 19248879 DOI: 10.1016/j.medcli.2008.11.024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
159 Roxburgh P, Evans TR. Systemic therapy of hepatocellular carcinoma: are we making progress? Adv Ther. 2008;25:1089-1104. [PMID: 18972075 DOI: 10.1007/s12325-008-0113-z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
160 Nakayama H, Takayama T. Management before hepatectomy for hepatocellular carcinoma with cirrhosis. World J Hepatol. 2015;7:2292-2302. [PMID: 26380653 DOI: 10.4254/wjh.v7.i20.2292] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
161 Song TJ, Ip EW, Fong Y. Hepatocellular carcinoma: current surgical management. Gastroenterology. 2004;127:S248-S260. [PMID: 15508091 DOI: 10.1053/j.gastro.2004.09.039] [Cited by in Crossref: 152] [Cited by in F6Publishing: 149] [Article Influence: 8.9] [Reference Citation Analysis]
162 Müller C. Hepatocellular carcinoma – Rising incidence, changing therapeutic strategies. Wien Med Wochenschr 2006;156:404-9. [DOI: 10.1007/s10354-006-0316-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
163 Zhuang PY, Shen J, Zhu XD, Zhang JB, Tang ZY, Qin LX, Sun HC. Direct transformation of lung microenvironment by interferon-α treatment counteracts growth of lung metastasis of hepatocellular carcinoma. PLoS One 2013;8:e58913. [PMID: 23527047 DOI: 10.1371/journal.pone.0058913] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
164 Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S. Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006;26:964-975. [PMID: 16953837 DOI: 10.1111/j.1478-3231.2006.01321.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
165 Harada N, Hiramatsu N, Oze T, Tatsumi T, Hayashi N, Takehara T. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma-A retrospective multicenter study: PegIFN/RBV Therapy After HCC Treatment. J Med Virol 2015;87:1199-206. [DOI: 10.1002/jmv.24173] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
166 Hassoun Z, Gores GJ. What surgeons should know about viral hepatitis and hepatocellular carcinoma. Surg Oncol Clin N Am. 2003;12:1-11. [PMID: 12735125 DOI: 10.1016/S1055-3207(02)00081-9] [Reference Citation Analysis]
167 Kubo S, Tanaka H, Takemura S, Yamamoto S, Hai S, Ichikawa T, Kodai S, Shinkawa H, Shuto T, Hirohashi K. Surgical Treatment for Hepatocellular Carcinoma Detected After Successful Interferon Therapy. Surg Today 2007;37:285-90. [DOI: 10.1007/s00595-006-3403-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
168 Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J, EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430. [PMID: 11592607 DOI: 10.1016/s0168-8278(01)00130-1] [Cited by in Crossref: 3112] [Cited by in F6Publishing: 1023] [Article Influence: 163.8] [Reference Citation Analysis]
169 Kaplan DE, Reddy KR. Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomes. Clin Liver Dis 2003;7:683-714. [PMID: 14509534 DOI: 10.1016/s1089-3261(03)00060-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
170 Martin RC, Jarnagin WR. Randomized Clinical Trials in Hepatocellular Carcinoma and Biliary Cancer. Surgical Oncology Clinics of North America 2002;11:193-205. [DOI: 10.1016/s1055-3207(03)00081-4] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
171 Lai CJ, Terrault NA. Antiviral therapy in patients with chronic hepatitis B and cirrhosis. Gastroenterol Clin North Am 2004;33:629-54, x-xi. [PMID: 15324948 DOI: 10.1016/j.gtc.2004.05.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
172 Fujimori M, Takaki H, Nakatsuka A, Uraki J, Yamanaka T, Hasegawa T, Shiraki K, Takei Y, Sakuma H, Yamakado K. Survival with up to 10-year follow-up after combination therapy of chemoembolization and radiofrequency ablation for the treatment of hepatocellular carcinoma: single-center experience. J Vasc Interv Radiol 2013;24:655-66. [PMID: 23428356 DOI: 10.1016/j.jvir.2012.12.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
173 Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat. 2010;17:287-292. [PMID: 19732321 DOI: 10.1111/j.1365-2893.2009.01181.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 74] [Article Influence: 6.2] [Reference Citation Analysis]
174 Wu MY, Yiang GT, Cheng PW, Chu PY, Li CJ. Molecular Targets in Hepatocarcinogenesis and Implications for Therapy. J Clin Med. 2018;7. [PMID: 30104473 DOI: 10.3390/jcm7080213] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
175 Helton WS, Di Bisceglie A, Chari R, Schwartz M, Bruix J. Treatment strategies for hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 2003;7:401-11. [PMID: 12654567 DOI: 10.1016/s1091-255x(02)00161-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
176 Nissen NN, Martin P. Hepatocellular Carcinoma: The High-Risk Patient. Journal of Clinical Gastroenterology 2002;35:S79-85. [DOI: 10.1097/00004836-200211002-00003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 2.9] [Reference Citation Analysis]
177 Sun HC, Tang ZY. Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives. J Cancer Res Clin Oncol. 2004;130:307-319. [PMID: 15034787 DOI: 10.1007/s00432-003-0530-y] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 3.9] [Reference Citation Analysis]
178 Ueno M, Uchiyama K, Ozawa S, Hayami S, Shigekawa Y, Tani M, Yamaue H. Adjuvant chemolipiodolization reduces early recurrence derived from intrahepatic metastasis of hepatocellular carcinoma after hepatectomy. Ann Surg Oncol. 2011;18:3624-3631. [PMID: 21614626 DOI: 10.1245/s10434-011-1800-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
179 Tsuchiya N, Sawada Y, Endo I, Uemura Y, Nakatsura T. Potentiality of immunotherapy against hepatocellular carcinoma. World J Gastroenterol. 2015;21:10314-10326. [PMID: 26420958 DOI: 10.3748/wjg.v21.i36.10314] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
180 Poon RT, Fan ST, O'Suilleabhain CB, Wong J. Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy. J Am Coll Surg 2002;195:311-8. [PMID: 12229937 DOI: 10.1016/s1072-7515(02)01226-7] [Cited by in Crossref: 80] [Cited by in F6Publishing: 33] [Article Influence: 4.2] [Reference Citation Analysis]
181 Yamazaki S, Takayama T. Surgical treatment of hepatocellular carcinoma: evidence-based outcomes. World J Gastroenterol. 2008;14:685-692. [PMID: 18205256 DOI: 10.3748/wjg.14.685.] [Reference Citation Analysis]
182 Ng KM, Niu R, Yan TD, Zhao J, McKay E, Chu FC, Morris DL. Adjuvant lipiodol I-131 after curative resection/ablation of hepatocellular carcinoma. HPB (Oxford) 2008;10:388-95. [PMID: 19088923 DOI: 10.1080/13651820802074449] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
183 Nojiri S, Joh T. Albumin suppresses human hepatocellular carcinoma proliferation and the cell cycle. Int J Mol Sci 2014;15:5163-74. [PMID: 24663086 DOI: 10.3390/ijms15035163] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
184 Hoshida Y, Shiratori Y, Omata M. Cost-effectiveness of adjuvant interferon therapy after surgical resection of Hepatitis C-related hepatocellular carcinoma: Interferon after resection of HCC. Liver 2002;22:479-85. [DOI: 10.1034/j.1600-0676.2002.01736.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
185 Hiroishi K, Eguchi J, Baba T, Shimazaki T, Ishii S, Hiraide A, Sakaki M, Doi H, Uozumi S, Omori R, Matsumura T, Yanagawa T, Ito T, Imawari M. Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J Gastroenterol. 2010;45:451-458. [PMID: 19936602 DOI: 10.1007/s00535-009-0155-2] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 6.0] [Reference Citation Analysis]
186 Gerard B, Bleiberg H. Treatment of hepatocarcinoma. Curr Oncol Rep 2004;6:184-91. [PMID: 15066229 DOI: 10.1007/s11912-004-0048-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
187 Solmi L, Nigro G, Roda E. Therapeutic effectiveness of echo-guided percutaneous radiofrequency ablation therapy with a LeVeen needle electrode in hepatocellular carcinoma. World J Gastroenterol 2006;12:1098-104. [PMID: 16534852 DOI: 10.3748/wjg.v12.i7.1098] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
188 Tu T, Budzinska MA, Maczurek AE, Cheng R, Di Bartolomeo A, Warner FJ, McCaughan GW, McLennan SV, Shackel NA. Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci. 2014;15:9422-9458. [PMID: 24871369 DOI: 10.3390/ijms15069422] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 6.7] [Reference Citation Analysis]
189 Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Tanaka J, Yoshizawa H. Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus. J Gastroenterol. 2011;46:536-544. [PMID: 21132575 DOI: 10.1007/s00535-010-0349-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
190 Sasaki K, Shindoh J, Nishioka Y, Sugawara T, Margonis GA, Andreatos N, Pawlik TM, Hashimoto M. Postoperative low hepatitis C virus load predicts long-term outcomes after hepatectomy for hepatocellular carcinoma. J Surg Oncol 2018;117:902-11. [PMID: 29473962 DOI: 10.1002/jso.25015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
191 Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol. 2005;3:27. [PMID: 15907199 DOI: 10.1186/1477-7819-3-27] [Cited by in Crossref: 85] [Cited by in F6Publishing: 77] [Article Influence: 5.3] [Reference Citation Analysis]
192 Bruix J, Sherman M;  Practice Guidelines Committee;  American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236. [PMID: 16250051 DOI: 10.1002/hep.20933] [Cited by in Crossref: 4104] [Cited by in F6Publishing: 3725] [Article Influence: 256.5] [Reference Citation Analysis]
193 Simonetti RG, Gluud C, Pagliaro L; Cochrane Hepato-Biliary Group. Interferon for hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2021;2021. [DOI: 10.1002/14651858.cd003883] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
194 Akamatsu M, Yoshida H, Shiina S, Teratani T, Tateishi R, Obi S, Sato S, Koike Y, Fujishima T, Ishikawa T, Shiratori Y, Omata M. Neither hepatitis C virus genotype nor virus load affects survival of patients with hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2004;16:459-66. [PMID: 15097037 DOI: 10.1097/00042737-200405000-00004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
195 Choi GH, Kim DH, Choi SB, Kang CM, Kim KS, Choi JS, Lee WJ, Han KH, Chon CY, Kim BR. The preoperative positivity for serum hepatitis B e antigen did not affect overall survival after curative resection of hepatitis B virus-related hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2009;24:391-8. [DOI: 10.1111/j.1440-1746.2008.05637.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
196 Jeong S, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol 2007;13:5188-95. [PMID: 17876889 DOI: 10.3748/wjg.v13.i39.5188] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
197 Ikeda K, Kobayashi M, Seko Y, Imai N, Hirakawa M, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H. Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer. Hepatol Res 2010;40:1168-75. [PMID: 20849431 DOI: 10.1111/j.1872-034X.2010.00720.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
198 Akateh C, Black SM, Conteh L, Miller ED, Noonan A, Elliott E, Pawlik TM, Tsung A, Cloyd JM. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol. 2019;25:3704-3721. [PMID: 31391767 DOI: 10.3748/wjg.v25.i28.3704] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 29] [Article Influence: 37.0] [Reference Citation Analysis]
199 Li Y, Martin RC 2nd. Herbal medicine and hepatocellular carcinoma: applications and challenges. Evid Based Complement Alternat Med 2011;2011:541209. [PMID: 21799681 DOI: 10.1093/ecam/neq044] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
200 Marı́n-hargreaves G, Azoulay D, Bismuth H. Hepatocellular carcinoma: surgical indications and results. Critical Reviews in Oncology/Hematology 2003;47:13-27. [DOI: 10.1016/s1040-8428(02)00213-5] [Cited by in Crossref: 55] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
201 Lee D, Chung YH, Kim JA, Park WH, Jin YJ, Shim JH, Ryu SH, Jang MK, Yu E, Lee YJ. Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma. Cancer. 2013;119:2239-2246. [PMID: 23564564 DOI: 10.1002/cncr.28082] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
202 Namiki I, Nishiguchi S, Hino K, Suzuki F, Kumada H, Itoh Y, Asahina Y, Tamori A, Hiramatsu N, Hayashi N. Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:347-368. [PMID: 20394674 DOI: 10.1111/j.1872-034x.2010.00642.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
203 Yamamoto M, Takasaki K, Otsubo T, Katsuragawa H, Katagiri S, Yoshitoshi K, Ariizumi S, Saito A, Nakano M. Favorable surgical outcomes in patients with early hepatocellular carcinoma. Ann Surg 2004;239:395-9. [PMID: 15075658 DOI: 10.1097/01.sla.0000114215.03112.e0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.5] [Reference Citation Analysis]
204 Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;32:851-858. [PMID: 20659285 DOI: 10.1111/j.1365-2036.2010.04414.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 78] [Article Influence: 8.5] [Reference Citation Analysis]
205 Kubo S. Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapy. Clin J Gastroenterol 2009;2:65-70. [DOI: 10.1007/s12328-009-0072-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
206 Takami Y, Eguchi S, Tateishi M, Ryu T, Mikagi K, Wada Y, Saitsu H. A randomised controlled trial of meloxicam, a Cox-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment. Hepatol Int 2016;10:799-806. [PMID: 26846471 DOI: 10.1007/s12072-016-9704-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
207 Zhong J, Zhong Q, Li L, Li H. Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review. Tumor Biol 2014;35:9459-68. [DOI: 10.1007/s13277-014-2443-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
208 Fukuda S, Itamoto T, Amano H, Kohashi T, Ohdan H, Tashiro H, Asahara T. Clinicopathologic features of hepatocellular carcinoma patients with compensated cirrhosis surviving more than 10 years after curative hepatectomy. World J Surg. 2007;31:345-352. [PMID: 17219274 DOI: 10.1007/s00268-006-0513-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
209 Toshikuni N, Arisawa T, Tsutsumi M. Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality. World J Gastroenterol. 2014;20:2876-2887. [PMID: 24659879 DOI: 10.3748/wjg.v20.i11.2876] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
210 Hosseini-Moghaddam SM, Mousavi A, Alavian SM. Is {beta}-interferon a promising therapeutic option for the management of hepatitis C? J Antimicrob Chemother. 2009;63:1097-1103. [PMID: 19329508 DOI: 10.1093/jac/dkp092] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
211 Huang TS, Shyu YC, Chen HY, Yuan SS, Shih JN, Chen PJ. A systematic review and meta-analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis-related hepatocellular carcinoma. J Viral Hepat. 2013;20:729-743. [PMID: 24010648 DOI: 10.1111/jvh.12096] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
212 Poon RT, Ng IO, Fan S, Lai EC, Lo C, Liu C, Wong J. Clinicopathologic Features of Long-Term Survivors and Disease-Free Survivors After Resection of Hepatocellular Carcinoma: A Study of a Prospective Cohort. JCO 2001;19:3037-44. [DOI: 10.1200/jco.2001.19.12.3037] [Cited by in Crossref: 113] [Cited by in F6Publishing: 46] [Article Influence: 5.7] [Reference Citation Analysis]
213 Ishikawa T. Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients. World J Gastroenterol. 2008;14:6140-6144. [PMID: 18985803 DOI: 10.3748/wjg.14.6140] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
214 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Reference Citation Analysis]
215 Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543-1554. [PMID: 17133492 DOI: 10.1002/hep.21415] [Cited by in Crossref: 252] [Cited by in F6Publishing: 236] [Article Influence: 18.0] [Reference Citation Analysis]
216 Kobayashi T, Ishiyama K, Ohdan H. Prevention of recurrence after curative treatment for hepatocellular carcinoma. Surg Today 2013;43:1347-54. [DOI: 10.1007/s00595-012-0473-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
217 Zhuang P, Zhang J, Zhang W, Zhu X, Liang Y, Xu H, Xiong Y, Kong L, Wang L, Wu W, Tang Z, Qin L, Sun H. Long-term interferon-α treatment suppresses tumor growth but promotes metastasis capacity in hepatocellular carcinoma. J Cancer Res Clin Oncol 2010;136:1891-900. [DOI: 10.1007/s00432-010-0848-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
218 Zhang W, Zhang B, Chen XP. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Front Med 2021;15:155-69. [PMID: 33754281 DOI: 10.1007/s11684-021-0848-3] [Reference Citation Analysis]
219 Zhang W, Song TQ, Zhang T, Wu Q, Kong DL, Li Q, Sun HC. Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: A meta-analysis with comparison of different types of hepatitis. Mol Clin Oncol. 2014;2:1125-1134. [PMID: 25279210 DOI: 10.3892/mco.2014.386] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
220 Sala M, Fuster J, Llovet JM, Navasa M, Solé M, Varela M, Pons F, Rimola A, García-Valdecasas JC, Brú C. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl. 2004;10:1294-1300. [PMID: 15376311 DOI: 10.1002/lt.20202] [Cited by in Crossref: 223] [Cited by in F6Publishing: 197] [Article Influence: 13.9] [Reference Citation Analysis]
221 Zamor PJ, deLemos AS, Russo MW. Viral hepatitis and hepatocellular carcinoma: etiology and management. J Gastrointest Oncol 2017;8:229-42. [PMID: 28480063 DOI: 10.21037/jgo.2017.03.14] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 15.0] [Reference Citation Analysis]
222 Johnson P, Bruix J. Hepatocellular carcinoma and the art of prognostication. Journal of Hepatology 2000;33:1006-8. [DOI: 10.1016/s0168-8278(00)80137-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
223 Zhang Z, Zhang Y, Wang W, Hua Y, Liu L, Shen S, Peng B. Thrombocytopenia and the outcomes of hepatectomy for hepatocellular carcinoma: a meta-analysis. J Surg Res. 2017;210:99-107. [PMID: 28457347 DOI: 10.1016/j.jss.2016.11.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
224 Li M, Lu C, Cheng J, Zhang J, Cao C, Xu J, Xu J, Pan H, Zhong B, Tucker S. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 2009;24:1437-1444. [PMID: 19486255 DOI: 10.1111/j.1440-1746.2009.05863.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
225 Muscari F, Foppa B, Carrere N, Kamar N, Peron J, Suc B. Resection of a Transplantable Single-Nodule Hepatocellular Carcinoma in Child-Pugh Class A Cirrhosis: Factors Affecting Survival and Recurrence. World J Surg 2011;35:1055-62. [DOI: 10.1007/s00268-011-1000-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
226 Wang CC, Kao JH. How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma? Expert Opin Pharmacother 2016;17:911-9. [PMID: 26831361 DOI: 10.1517/14656566.2016.1149165] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
227 Méndez-Sánchez N, Ridruejo E, Alves de Mattos A, Chávez-Tapia NC, Zapata R, Paraná R, Mastai R, Strauss E, Guevara-Casallas LG, Daruich J, Gadano A, Parise ER, Uribe M, Aguilar-Olivos NE, Dagher L, Ferraz-Neto BH, Valdés-Sánchez M, Sánchez-Avila JF. Latin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinoma. Ann Hepatol 2014;13 Suppl 1:S4-40. [PMID: 24998696 [PMID: 24998696 DOI: 10.1016/s1665-2681(19)30919-6] [Cited by in Crossref: 17] [Article Influence: 2.8] [Reference Citation Analysis]
228 Nagaoki Y, Imamura M, Nishida Y, Daijo K, Teraoka Y, Honda F, Nakamura Y, Morio K, Fujino H, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Miki D, Hiyama Y, Ochi H, Chayama K, Aikata H. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy: NAGAOKI et al.. J Med Virol 2019;91:650-8. [DOI: 10.1002/jmv.25352] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
229 Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2005;11:7391-7400. [PMID: 16437707 DOI: 10.3748/wjg.v11.i47.7391] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 89] [Article Influence: 2.4] [Reference Citation Analysis]
230 Miyatake H, Kobayashi Y, Iwasaki Y, Nakamura S, Ohnishi H, Kuwaki K, Toshimori J, Hagihara H, Nouso K, Yamamoto K. Effect of Previous Interferon Treatment on Outcome After Curative Treatment for Hepatitis C Virus-Related Hepatocellular Carcinoma. Dig Dis Sci 2012;57:1092-101. [DOI: 10.1007/s10620-011-1934-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
231 Joko K, Goto T, Watanabe H, Mitsuda A, Uchida Y, Hasebe C, Tsuruta S, Kimura H, Koike T, Akamatsu T, Mashiba T, Ochi H, Nakamura Y, Tsuchiya K, Kurosaki M, Izumi N. Effects of antiviral therapy for hepatitis C following treatment of hepatocellular carcinoma: survey findings of the Japanese Red Cross Liver Study Group: Anti-HCV Therapy Post HCC Treatment. Hepatol Res 2016;46:251-8. [DOI: 10.1111/hepr.12515] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
232 Zacharoulis D, Hatzitheofilou C, Athanasiou E, Zacharoulis S. Antiangiogenic strategies in hepatocellular carcinoma: current status. Expert Review of Anticancer Therapy 2014;5:645-56. [DOI: 10.1586/14737140.5.4.645] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
233 Obora A, Shiratori Y, Okuno M, Adachi S, Takano Y, Matsushima-Nishiwaki R, Yasuda I, Yamada Y, Akita K, Sano T. Synergistic induction of apoptosis by acyclic retinoid and interferon-beta in human hepatocellular carcinoma cells. Hepatology. 2002;36:1115-1124. [PMID: 12395321 DOI: 10.1053/jhep.2002.36369] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
234 Rougier P, Mitry E, Barbare JC, Taieb J. Hepatocellular carcinoma (HCC): an update. Semin Oncol. 2007;34:S12-S20. [PMID: 17449346 DOI: 10.1053/j.seminoncol.2007.01.007] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
235 Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, Mok KT, Lee WC, Yeh HZ, Ho MC. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol. 2009;50:958-968. [PMID: 19303160 DOI: 10.1016/j.jhep.2008.12.023] [Cited by in Crossref: 109] [Cited by in F6Publishing: 97] [Article Influence: 9.1] [Reference Citation Analysis]
236 Imakiire K, Uto H, Sato Y, Sasaki F, Mawatari S, Ido A, Shimoda K, Hayashi K, Stuver SO, Ito Y. Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C. Mol Med Rep. 2012;6:259-264. [PMID: 22614103 DOI: 10.3892/mmr.2012.924] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
237 Yamakado K, Nakatsuka A, Takaki H, Yokoi H, Usui M, Sakurai H, Isaji S, Shiraki K, Fuke H, Uemoto S. Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology. 2008;247:260-266. [PMID: 18305190 DOI: 10.1148/radiol.2471070818] [Cited by in Crossref: 132] [Cited by in F6Publishing: 111] [Article Influence: 10.2] [Reference Citation Analysis]
238 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 572] [Article Influence: 165.3] [Reference Citation Analysis]
239 Hung C, Lee C, Wang J, Tung H, Chen C, Lu S. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol 2005;20:1553-9. [DOI: 10.1111/j.1440-1746.2005.03925.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]